Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) and Reliv’ International (OTCMKTS:RELV – Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.
Institutional & Insider Ownership
11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 7.8% of Reliv’ International shares are owned by institutional investors. 0.3% of Decoy Therapeutics shares are owned by company insiders. Comparatively, 30.0% of Reliv’ International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings for Decoy Therapeutics and Reliv’ International, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Decoy Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Reliv’ International | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares Decoy Therapeutics and Reliv’ International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Decoy Therapeutics | N/A | -395.42% | -193.30% |
| Reliv’ International | -0.61% | -1.89% | -1.31% |
Volatility & Risk
Decoy Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Reliv’ International has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500.
Valuation and Earnings
This table compares Decoy Therapeutics and Reliv’ International”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Decoy Therapeutics | N/A | N/A | -$12.52 million | ($106.90) | -0.07 |
| Reliv’ International | $35.06 million | 0.11 | -$440,000.00 | ($0.09) | -25.00 |
Reliv’ International has higher revenue and earnings than Decoy Therapeutics. Reliv’ International is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Decoy Therapeutics beats Reliv’ International on 7 of the 13 factors compared between the two stocks.
About Decoy Therapeutics
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
About Reliv’ International
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.
Receive News & Ratings for Decoy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decoy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
